Industry Profile: Indian Pharmaceutical sector is among the fastest-growing markets and is the third-largest market by volume and thirteen by value. It is expected that the Indian pharma industry will grow with a 15% CAGR between 2015-20. The Indian pharmaceutical industry is expected to become $55 billion by 2020, emerging as the sixth-largest pharmaceutical market by absolute size. India is the largest supplier of generic drug global exports, with 20% by volume. Indian companies supply 80% of Anti-retro-viral drugs used against AIDS worldwide.
India maintains its lead over China in pharmaceutical export with 11.44% year-on-year growth to $12.91 billion. Drug approval to Indian pharma from US FDA is also increased by nearly double, but with substantial inspections, the biggest problem for many Indian companies now.
All due to support from govt of India, the sector is thriving and surviving against global competition. The farmaceutical industry is permitted to receive 100% FDI under the automatic route, so the sector attracted FDI inflows of about $ 14.53 billion between April 2000 and December 2016. many Global companies like Abbott and GSK are investing in India. In addition, the UN-backed Medicine Patent pool signed six sublicenses with Aurobindo, Cipla Disano, Emcure, Hetero Labs, and Laurus Labs to manufacture anti-AIDS medicine for 112 developing countries.
Company Profile: Cipla, a multinational pharma company, headquarters in Mumbai, Maharashtra. The company was incorporated in 1935. The company is mainly Research-oriented, having 20+ R&D Centres worldwide. The company operates in around 80+ countries with more than 1500 products that are manufactured in 35 manufacturing units. The company manufactures different products. Tablets, Capsule, Sealed eye drop, syringe barrel, API, Oral Liquid. Company manufacturing products for different segments. From urology, Retroviral, dermatology, oncology, cardiovascular, malaria, HIV AIDS. The company is one of the leading manufacturers of medicine for malaria.
Shareholding Pattern: BSE Data
Financials and Ratios. : [table id=35 /]
Future Prospects: Even after an extensive product portfolio, the company’s revenue decreases. it is not shocking as the whole pharma sector is going from pain, and so the
